Personalized Medicine's Coming of Age: One Drug, One Patient.
Where this comes from
- Record sourced from PubMed, PMID 37733765.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2194.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity. See related article by Chung et al., p. 4784.
Medical subject headings
- Precision Medicine
- Multiple Myeloma